Showing 1-10 of 627 Results
Aijaz Ahmed, MD
Associate Professor of Medicine (Gastroenterology and Hepatology) at the Stanford University Medical Center
Bio My research interests include nonalcoholic fatty liver disease (NAFLD) and viral hepatitis. I have focused my research to database analysis/outcomes and translational research in these areas. While database analysis has been critical in outlining trends in NAFLD and viral hepatitis epidemiology, translational research has provided insight into disease mechanism and future therapies. I collaborate with several basic science colleagues and act as clinical mentor for young investigators involved in translational research. I am also interested and act as adjunct faculty in biodesign and health policy. I have participated in several clinical trials as a co-investigator.
Ash A. Alizadeh, MD/PhD
Assistant Professor of Medicine (Oncology)
Current Research and Scholarly Interests My research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.
Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.
Russ B. Altman
Kenneth Fong Professor and Professor of Bioengineering, of Genetics, of Medicine (General Medical Discipline), of Biomedical Data Science and, by courtesy, of Computer Science
Current Research and Scholarly Interests I refer you to my web page for detailed list of interests, projects and publications. In addition to pressing the link here, you can search "Russ Altman" on http://www.google.com/
Professor of Neurology at the Stanford University Medical Center
Current Research and Scholarly Interests Our research focuses on the investigation of the brain’s innate immune response, and the role that maladaptive microglial activity plays in initiation and progression of neurological disease.
Assistant Professor of Medicine (Infectious Diseases) and, by courtesy, of Health Research and Policy (Epidemiology)
Current Research and Scholarly Interests Our laboratory aims to develop and test innovative approaches to the diagnosis, treatment and control of infectious diseases in resource-limited settings. We draw upon multiple fields including mathematical modeling, microbial genetics, field epidemiology, statistical inference and biodesign to work on challenging problems in infectious diseases, with an emphasis on tuberculosis and tropical diseases.
Thomas P. Andriacchi
Professor of Mechanical Engineering and of Orthopaedic Surgery, Emeritus
Current Research and Scholarly Interests Professor Andriacchi's research focuses on the biomechanics of human locomotion and applications to medical devices, sports injury, osteoarthritis, the anterior cruciate ligament and low cost prosthetic limbs
Martin S. Angst
Professor of Anesthesiology, Perioperative and Pain Medicine at the Stanford University Medical Center
Current Research and Scholarly Interests Our laboratory's current transformative research efforts focus on studying immune health in the context of surgery and anesthesia.
Justin P. Annes M.D., Ph.D.
Assistant Professor of Medicine (Endocrinology)
Current Research and Scholarly Interests The ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders
The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.
(1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.
(2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.
HEREDIATY PARAGAGLIOMA SYNDROME
The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.
As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.